Can I restart methotrexate now that my facial rash (likely herpes zoster) has been present for three weeks, and what should I do about antiviral therapy, eye examination, post‑herpetic neuralgia pain management, and zoster vaccination?

Restarting Methotrexate After Herpes Zoster

Direct Answer

You should restart methotrexate only after all herpes zoster lesions have completely scabbed and crusted, which typically occurs 2-4 weeks after rash onset, and you should receive the recombinant zoster vaccine (Shingrix) after recovery to prevent future episodes. 1

---

Antiviral Therapy Decision

At three weeks post-rash onset, your antiviral therapy decision depends on lesion status:

• If all lesions have completely scabbed: Antiviral therapy can be discontinued, as the key clinical endpoint is complete crusting of all lesions, not an arbitrary time period. 1, 2

• If active vesicles or new lesions are still forming: Continue antiviral therapy (valacyclovir 1 gram three times daily or acyclovir 800 mg five times daily) until all lesions have completely scabbed. 1, 2

• If you are immunocompromised or on methotrexate: You may require extended antiviral treatment beyond the typical 7-10 days, as immunosuppressed patients develop new lesions for 7-14 days and heal more slowly. 1

---

Timing of Methotrexate Restart

The critical decision point is complete lesion crusting, not calendar days:

• Methotrexate should be temporarily reduced or discontinued during active herpes zoster infection, particularly if the infection is disseminated or invasive. 1

• Re-introduction of immunosuppressive agents like methotrexate is recommended only after all vesicular lesions have crusted, fever has resolved (if present), and you have shown clinical improvement. 1

• At three weeks, most immunocompetent patients will have complete crusting, but verify this clinically before restarting. 1, 2

• If you are immunocompromised, healing may take longer than three weeks, and you should wait for complete resolution before resuming methotrexate. 1

---

Eye Examination Requirements

Ophthalmologic evaluation is mandatory if you have facial involvement:

• Facial herpes zoster carries risk of ophthalmic complications and cranial nerve involvement, requiring urgent ophthalmologic assessment. 1

• If you have not yet had an eye examination and your rash involved the face (particularly the tip of the nose, indicating nasociliary nerve involvement), schedule an urgent ophthalmology consultation even at three weeks post-onset. 1

• Ophthalmic zoster can cause vision-threatening complications including keratitis, uveitis, and acute retinal necrosis. 3

---

Post-Herpetic Neuralgia Management

If you are experiencing persistent pain at three weeks, initiate PHN-specific therapy:

First-Line Systemic Agents (in order of recommendation):

• Gabapentin or pregabalin (anticonvulsants) are the preferred first-line agents for post-herpetic neuralgia. 4

• Tricyclic antidepressants (amitriptyline, nortriptyline, or desipramine) are effective second-line options. 4

• Opioid analgesics (tramadol, morphine, oxycodone, or methadone) should be reserved for severe pain unresponsive to first-line agents. 4

Topical Options:

• Topical lidocaine patches are effective for localized pain and have minimal systemic side effects. 4

• Topical capsaicin can be considered, though it may cause initial burning sensation. 4

Preventive Consideration:

• Early initiation of gabapentin or amitriptyline during the acute phase (which you are now past) reduces the risk of developing post-herpetic neuralgia. 4, 3

---

Zoster Vaccination Strategy

The recombinant zoster vaccine (Shingrix) is strongly recommended after recovery:

• The CDC recommends Shingrix for all adults aged 50 years and older, regardless of prior herpes zoster episodes, providing >90% efficacy in preventing future recurrences. 1, 2

• Administer the vaccine after complete recovery from your current episode (all lesions crusted and healed). 1

• Timing relative to methotrexate restart: Ideally, give Shingrix at least 4 weeks before resuming methotrexate to maximize immunogenicity, though it can be given after restarting if necessary. 1

• Shingrix is a two-dose series (0 and 2-6 months) and is not a live vaccine, making it safe for immunosuppressed patients. 1, 3

• The vaccine reduces the risk of future herpes zoster by over 90% and significantly decreases the burden of post-herpetic neuralgia. 5, 6

---

Clinical Algorithm for Methotrexate Restart

Follow this stepwise approach:

1. Verify complete lesion crusting: All vesicles must be scabbed with no new lesions forming. 1

2. Confirm resolution of systemic symptoms: No fever, and clinical improvement documented. 1

3. Complete ophthalmologic evaluation if facial involvement: Rule out ocular complications before immunosuppression. 1

4. Discontinue antiviral therapy: Once all lesions are crusted. 1, 2

5. Restart methotrexate at previous dose: No dose adjustment needed unless other clinical factors have changed. 7

6. Schedule Shingrix vaccination: Administer after recovery, ideally before or shortly after methotrexate restart. 1, 2

7. Monitor for disease flare: Watch for recurrence of the condition methotrexate was treating (atopic dermatitis, psoriasis, or rheumatoid arthritis). 8

---

Important Caveats

• Do not restart methotrexate if lesions are still active: This increases risk of disseminated infection and severe complications. 1

• Methotrexate discontinuation does not cause urticaria: If you develop new rash after stopping methotrexate, this represents either disease flare of your underlying condition or a coincidental new process, not a withdrawal effect. 8

• Infection control until fully crusted: Avoid contact with pregnant women, immunocompromised individuals, and those without varicella immunity until all lesions are completely crusted. 1

• Higher risk of severe zoster on methotrexate: Your baseline immunosuppression increases risk of future episodes, making Shingrix vaccination particularly important. 1, 3